Curie Therapeutics Recognized as a 2022 Prix Galien USA Nominee for Prix Galien Startup
Curie Therapeutics Recognized as a 2022 Prix Galien USA Nominee for Prix Galien Startup

News & Media

The latest on Curie Therapeutics
Curie Therapeutics Recognized as a 2022 Prix Galien USA Nominee for Prix Galien Startup

CAMBRIDGE, Mass., August 17, 2022 – Curie Therapeutics Inc. (“Curie”), a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, today announced that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Curie a 2022 Prix Galien USA Award nominee for “Prix Galien Startup.” Winners will be announced during the Prix Galien USA Awards Ceremony on October 27, 2022, at the American Museum of Natural History in New York City.

“Being named a Prix Galien USA Nominee recognizes the innovation we are bringing to the field of radiopharmaceuticals as Curie strives to greatly improve treatments for patients with solid tumors,” said Simon Read, Ph.D., Curie Founder and Chief Executive Officer. “While the treatment of hematological malignancies has been transformed by new therapeutic innovations, solid tumors remain difficult to treat. At Curie, we are aiming to harness the destructive efficiency of radiation, delivered by molecules targeting proteins found uniquely in cancer to kill tumor cells. With this powerful combination, our mission is to bring together cutting-edge peptide drug discovery with recent developments in radiochemistry, and we are building a fully integrated company that can manufacture its own drugs and take them to the bedside.”

The Prix Galien was created in France in 1970 to reward innovative treatments and technologies that improve human health. It is seen as an influential event to those interested in pharmaceutical development and is widely considered the industry’s highest accolade for pharmaceutical research and development.

“The Prix Galien Awards have become the most coveted prizes for those who dedicate their lives to the development of meaningful drugs and innovations,” said Bernard Poussot, Director, Roche Holding, Former Chairman & CEO, Wyeth, Prix Galien Startup, Digital Health and Incubators, Accelerators and Equity Committee Chairman. “Members of the Awards Committees applaud the unwavering commitment of each nominee in their quest to provide a healthier future for the next generation.”

The “Prix Galien Startup” category, which rewards and supports innovation worldwide, will announce three winners for, “Best Startup in Pharmaceutical or Biotechnology Industry,” “Best Startup in the Medical Technologies Industry,” and “Best Startup in the Digital Health Industry.” 

About the Galien Foundation

The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives. The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa. The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research. For more information, visit www.galienfoundation.org

About Business France

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program. For further information, visit www.businessfrance.fr

About Curie Therapeutics

Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie’s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie’s mission is to revolutionize the use of radiomedicines in cancer. 

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091